{"entity":{"id":"nct07099898","kind":"trial","name":"A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)","aka":[],"tldr":"A phase 3 trial of Topotecan in small-cell lung cancer, run by GlaxoSmithKline, now recruiting.","summary":"A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) is a phase 3 interventional study registered as NCT07099898 by GlaxoSmithKline, with 420 participants planned, started 2025-08-11 and due to reach its primary completion in 2027-11-05. Interventions recorded: Ris-Rez and Topotecan.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07099898","url":"https://clinicaltrials.gov/study/NCT07099898"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["sclc"],"sections":[],"technologies":["cytotoxic-chemotherapy","topoisomerase-inhibitors"],"targets":[],"drugs":["topotecan"],"companies":["gsk"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07099898","phase":"3","setting":"Phase 3, Multicenter, Randomized, Open-label Clinical Study of GSK5764227, a B7-H3 Antibody Drug Conjugate (ADC), Compared With Topotecan in Participants With Relapsed Small Cell Lung Cancer (SCLC)","sponsor":"GlaxoSmithKline","participation":[{"nct":"NCT07099898","source":"https://clinicaltrials.gov/study/NCT07099898","fetchedAt":"2026-10-07T16:55:25.997Z","studySha256":"d55f1418cfb874e3aff50a7a719504dad3b75bb7e5dd7bf654dd5e624a8c421c","overallStatus":"RECRUITING","lastUpdatePosted":"2026-09-28","leadSponsor":"GlaxoSmithKline","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":420,"enrolmentType":"ESTIMATED","siteCount":135,"recruitingSiteCount":132,"countries":["Argentina","Australia","Brazil","Bulgaria","Canada","Finland","France","Germany","Greece","Hungary","Ireland","Israel","Italy","Japan","Mexico","Poland","Portugal","Romania","South Korea","Spain","Sweden","Switzerland","Turkey (Türkiye)","United Kingdom","United States"]}],"started":"2025-08-11","startedType":"actual","enrolled":420,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07099898/","neighbours":{"cancer":[{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"drug":[{"id":"topotecan","kind":"drug","name":"Topotecan","route":"/drugs/topotecan/"}],"company":[{"id":"gsk","kind":"company","name":"GSK","route":"/companies/gsk/"}]}}